Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, has announced a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. for the commercialization of GelrinC, its proprietary implant for repairing damaged knee cartilage, in Israel. The agreement marks a significant step in the company's commercialization strategy for GelrinC, which has already received regulatory approval from Israel's Ministry of Health for the same indication approved in Europe and being pursued in the United States.
Under the terms of the agreement, AMI Medical Technologies will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to support the product's commercial introduction in Israel. The agreement includes minimum purchase requirements, with Regentis expecting initial revenue contributions beginning in 2027. The two companies will also collaborate to establish reimbursement coverage for GelrinC with Israel's leading health maintenance organizations (HMOs) and promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement coverage is established, patients may be able to access the implant through private health insurance.
This distribution agreement supports Regentis' broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel implant that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
The news is significant for Regentis as it represents a concrete step toward generating revenue from GelrinC, with the first contributions anticipated in 2027. For the orthopedic industry, the agreement highlights the growing interest in regenerative medicine solutions for cartilage repair, a condition that affects hundreds of thousands of patients annually. The collaboration with AMI Medical Technologies, which has deep relationships with Israeli orthopedic surgeons and healthcare providers, could accelerate the adoption of GelrinC in Israel and serve as a model for further commercialization efforts in other markets.
Regentis Biomaterials is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, the company's Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company's lead product, GelrinC, is at the forefront of this effort. For more information on Regentis Biomaterials, visit Regentis Biomaterials (NYSE American: RGNT). The full press release can be viewed at https://ibn.fm/gk9yG. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
This news was disseminated by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions via InvestorWire, among other services.
